The Use of Patient-Derived Tumor Tissue as a Preclinical Tool to Facilitate Identification, Validation and Monitoring of Factors Driving Cancer Development and Progression, Canada

Registration Status: Completed

Objective: Patient tumor samples obtained following standard of care surgical resection will be obtained and clinically annotated. Samples will be used to generate cell lines, organoids, patient-derived explants, or patient-derived xenograft models which will be used for testing of novel anti-cancer or cancer detection agents. Portions of samples will be snap frozen for future use to isolate RNA or protein for subsequent analysis, in addition to fixing a portion in formalin for validation of potential targets of interest by IHC methods.

Registered Biobank Name The Use of Patient-Derived Tumor Tissue as a Preclinical Tool to Facilitate Identification, Validation and Monitoring of Factors Driving Cancer Development and Progression
Biobank Leader Christina Addison
Country Canada
Email for biobank inquiries caddison@ohri.ca
Principal Investigator Christina Addison; Adam Shuhendler
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected: